LISINOPRIL TABLET

ประเทศ: แคนาดา

ภาษา: อังกฤษ

แหล่งที่มา: Health Canada

สารออกฤทธิ์:

LISINOPRIL (LISINOPRIL DIHYDRATE)

มีจำหน่ายจาก:

COBALT PHARMACEUTICALS COMPANY

รหัส ATC:

C09AA03

INN (ชื่อสากล):

LISINOPRIL

ปริมาณ:

20MG

แบบฟอร์มเภสัชกรรม:

TABLET

องค์ประกอบ:

LISINOPRIL (LISINOPRIL DIHYDRATE) 20MG

เส้นทางการบริหาร:

ORAL

หน่วยในแพ็คเกจ:

30/100/500

ประเภทใบสั่งยา:

Prescription

พื้นที่บำบัด:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

สรุปสินค้า:

Active ingredient group (AIG) number: 0121550002; AHFS:

สถานะการอนุญาต:

CANCELLED PRE MARKET

วันที่อนุญาต:

2017-09-01

สรุปลักษณะสินค้า

______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 1 of 44 _
_ _
_ _
PRODUCT MONOGRAPH
PR
LISINOPRIL
Lisinopril Tablets, USP
5 mg, 10 mg and 20 mg
(of Lisinopril as Lisinopril Dihydrate)
Angiotensin Converting Enzyme Inhibitor
Cobalt Pharmaceuticals Company
6500 Kitimat Road
Mississauga, Ontario
Canada, L5N 2B8
CONTROL NUMBER: 172480
Date of Revision:
March 4, 2014
______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 2 of 44 _
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
11
DRUG INTERACTIONS
.........................................................................................................
17
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
.......................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 23
STORAGE AND STABILITY
.................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.........................